AMYRIS, INC.: M&A transaction — Amyris closes $200M asset sale to Givaudan, buys remaining 49% of Aprinnova for $49M

AMYRIS, INC.

Sold cosmetic ingredients assets to Givaudan for $200M upfront cash plus up to $150M performance earnout over three years.
Total estimated value including near- and long-term manufacturing partnership is approximately $500M.
Purchased 49% of Aprinnova from Nikko Chemicals and Nissa for $49M cash, increasing Amyris ownership to 99%.
Both transactions closed on April 3, 2023, as previously announced.
Long-term partnership with Givaudan for Amyris to manufacture cosmetic ingredients.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

AMYRIS, INC. completed a disposition involving Givaudan SA for $200 million upfront cash consideration and up to $150 million in performance-based earnout payments over three years (closed 2023-04-03).

Action: disposition
Counterparty: Givaudan SA
Consideration: $200 million upfront cash consideration and up to $150 million in performance-based earnout payments over three years
Closing: 2023-04-03

Exact text from the filing

to distribute, market and sell Neossance® Squalane emollient, Neossance® Hemisqualane silicone alternative and CleanScreenTM sun protector in cosmetics actives, to Givaudan for $200 million upfront cash consideration and up to $150 million in performance-based earnout payments over three years. In addition, the parties entered into a long-term partnership agreement

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001365916-23-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.